ADPT Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -56.92% compared to Adaptive Biotechnologies's net margin of 24.92%. Adaptive Biotechnologies's return on equity of -62.62% beat Biomarin Pharmaceutical's return on equity of 9.62%.

Adaptive Biotechnologies has a consensus price target of $11.14, signalling upside risk potential of 17.05%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.91 which suggests that it could grow by 65.16%. Given that Biomarin Pharmaceutical has higher upside potential than Adaptive Biotechnologies, analysts believe Biomarin Pharmaceutical is more attractive than Adaptive Biotechnologies.

Adaptive Biotechnologies has a beta of 1.755, which suggesting that the stock is 75.472% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Adaptive Biotechnologies quarterly revenues are $52.4M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Adaptive Biotechnologies's net income of -$29.9M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 21.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 7.43x versus 3.89x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -56.92% compared to Adaptive Biotechnologies's net margin of -907.48%. Adaptive Biotechnologies's return on equity of -62.62% beat Moderna's return on equity of -29.23%.

Adaptive Biotechnologies has a consensus price target of $11.14, signalling upside risk potential of 17.05%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 79.58%. Given that Moderna has higher upside potential than Adaptive Biotechnologies, analysts believe Moderna is more attractive than Adaptive Biotechnologies.

Adaptive Biotechnologies has a beta of 1.755, which suggesting that the stock is 75.472% more volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Adaptive Biotechnologies quarterly revenues are $52.4M, which are smaller than Moderna quarterly revenues of $107M. Adaptive Biotechnologies's net income of -$29.9M is higher than Moderna's net income of -$971M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 7.43x versus 3.29x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -56.92% compared to Adaptive Biotechnologies's net margin of -49.65%. Adaptive Biotechnologies's return on equity of -62.62% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Adaptive Biotechnologies has a consensus price target of $11.14, signalling upside risk potential of 17.05%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 54.55%. Given that NovaBay Pharmaceuticals has higher upside potential than Adaptive Biotechnologies, analysts believe NovaBay Pharmaceuticals is more attractive than Adaptive Biotechnologies.

Adaptive Biotechnologies has a beta of 1.755, which suggesting that the stock is 75.472% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Adaptive Biotechnologies quarterly revenues are $52.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Adaptive Biotechnologies's net income of -$29.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 7.43x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -56.92% compared to Adaptive Biotechnologies's net margin of -271.3%. Adaptive Biotechnologies's return on equity of -62.62% beat Spero Therapeutics's return on equity of -108.26%.

Adaptive Biotechnologies has a consensus price target of $11.14, signalling upside risk potential of 17.05%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 100%. Given that Spero Therapeutics has higher upside potential than Adaptive Biotechnologies, analysts believe Spero Therapeutics is more attractive than Adaptive Biotechnologies.

Adaptive Biotechnologies has a beta of 1.755, which suggesting that the stock is 75.472% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.229, suggesting its less volatile than the S&P 500 by 77.125%.

Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Adaptive Biotechnologies quarterly revenues are $52.4M, which are larger than Spero Therapeutics quarterly revenues of $5.1M. Adaptive Biotechnologies's net income of -$29.9M is lower than Spero Therapeutics's net income of -$13.9M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 7.43x versus 4.81x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.